Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) shot up 13.8% during mid-day trading on Wednesday . The company traded as high as $2.60 and last traded at $2.56. 1,490,389 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 2,653,890 shares. The stock had previously closed at $2.25.
A number of brokerages recently issued reports on CATB. Wedbush reissued an “outperform” rating and issued a $4.00 target price on shares of Catabasis Pharmaceuticals in a research report on Wednesday, June 21st. HC Wainwright lifted their target price on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Monday, August 14th. Citigroup Inc. set a $3.50 target price on Catabasis Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, October 5th. Cowen and Company reissued a “market perform” rating and issued a $2.00 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th. Finally, Oppenheimer Holdings, Inc. lifted their target price on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an “outperform” rating in a research report on Thursday, October 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $5.42.
Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.08.
Several institutional investors have recently modified their holdings of the company. Virtu KCG Holdings LLC purchased a new stake in shares of Catabasis Pharmaceuticals in the second quarter worth approximately $271,000. Oppenheimer & Co. Inc. raised its stake in shares of Catabasis Pharmaceuticals by 33.3% in the second quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Catabasis Pharmaceuticals in the first quarter worth approximately $106,000. 32.90% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This article was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://sportsperspectives.com/2017/10/13/catabasis-pharmaceuticals-inc-catb-shares-up-13-8.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.